Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 4Terminated 3Unknown 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Hepatocellular 29Carcinoma, Renal Cell 17Liver Neoplasms 12Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Neoplasms 5Leukemia, Myeloid, Acute 5Kidney Neoplasms 5Neoplasm Metastasis 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Prostatic Neoplasms 3Lung Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Lymphocytic, Chronic, B-Cell 3Colorectal Neoplasms 3Carcinoma 3Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2Multiple Myeloma 2Breast Neoplasms, Male 2Blast Crisis 2Adenocarcinoma, Follicular 2Urethral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thyroid cancer, medullary 1

Interventions

Gemcitabine 25Cisplatin 19pembrolizumab 11avelumab 10Nivolumab 7Mitomycin 6Carboplatin 6apaziquone 5Paclitaxel 5Vinblastine 4Methotrexate 4Doxorubicin 4Docetaxel 4BCG Vaccine 4vofatamab 3durvalumab 3atezolizumab 3Sunitinib 3Standard of Care 3Sorafenib 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Radiation 3Magnetic Resonance Spectroscopy 3Lapatinib 3Cystectomy 3B701 protein, Human herpesvirus 6 3valrubicin 2rucaparib 2enfortumab vedotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Urinary Bladder Neoplasms × Sorafenib × Clear all
NCT00714948 2015-11-16

Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
2 enrolled 5 charts
Genitourinary

Urinary Bladder Neoplasms

NCT00112905 2014-05-30

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

National Cancer Institute (NCI)

Phase 2 Terminated
27 enrolled 8 charts
Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT01215266 2011-09-08

Sorafenib in Urothelium Cancer of Bladder

Association of Urologic Oncology (AUO)

Phase 2 Terminated
98 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡